✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Tivozanib hydrochlorideis the generic ingredient in one branded drug marketed by Aveo Pharms and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Tivozanib hydrochloride has forty-six patent family members in twenty-four countries.
One supplier is listed for this compound.
Recent Clinical Trials for tivozanib hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
|Genentech, Inc.||Phase 1/Phase 2|
|Aveo Oncology Pharmaceuticals||Phase 1/Phase 2|
|University of Florida||Phase 1/Phase 2|
Pharmacology for tivozanib hydrochloride
|Drug Class||Kinase Inhibitor |
|Mechanism of Action|| Tyrosine Kinase Inhibitors |
|Country||Patent Number||Title||Estimated Expiration|
|Japan||3602513||See Plans and Pricing|
|Japan||WO2004035572||Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−Ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形||See Plans and Pricing|
|Brazil||0209216||See Plans and Pricing|
|Mexico||PA03009662||DERIVADOS DE QUINOLINA Y DERIVADOS DE QUINAZOLINA QUE TIENEN GRUPOS AZOLILO. (QUINOLINE DERIVATIVE HAVING AZOLYL GROUP AND QUINAZOLINE DERIVATIVE.)||See Plans and Pricing|
|Denmark||1382604||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1382604||122018000018||Germany||See Plans and Pricing||PRODUCT NAME: TIVOZANIB ODER EIN SALZ ODER SOLVAT HIERVON; REGISTRATION NO/DATE: EU/1/17/1215 20170824|
|1382604||300927||Netherlands||See Plans and Pricing||DETAILS ASSIGNMENT: CHANGE OF OWNER(S), CHANGE OF OWNER(S) NAME|
|1382604||C201830013||Spain||See Plans and Pricing||PRODUCT NAME: TIVOZANIB O UNA SAL O SOLVATO DEL MISMO, EN PARTICULAR, EL HIDROCLORURO MONOHIDRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1215; DATE OF AUTHORISATION: 20170824; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1215; DATE OF FIRST AUTHORISATION IN EEA: 20170824|
|1382604||18C1006||France||See Plans and Pricing||PRODUCT NAME: TIVOZANIB OU UN DE SES SELS OU DE SES SOLVATES,EN PARTICULIER LE CHLORHYDRATE MONOHYDATE; REGISTRATION NO/DATE: EU/1/17/1215 20170829|
|1382604||CR 2018 00007||Denmark||See Plans and Pricing||PRODUCT NAME: TIVOZANIB ELLER ET SALT ELLER SOLVAT DERAF, SAERLIGT HYDROCHLORIDMONOHYDRATET; REG. NO/DATE: EU/1/17/1215 20170829|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.